Oxford Immunotec Global traded at $21.95 this Saturday March 6th, decreasing $0.04 or 0.18 percent since the previous trading session. Looking back, over the last four weeks, Oxford Immunotec Global lost 0.14 percent. Over the last 12 months, its price rose by 80.07 percent. Looking ahead, we forecast Oxford Immunotec Global to be priced at 21.40 by the end of this quarter and at 19.84 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Oxford Immunotec Global
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company. The Companys T-SPOT technology platform allows the Company to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human bodys immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. The initial product it has developed using its T-SPOT technology platform is its T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection (LTBI). In August 2014, the Company acquired Boulder Diagnostics Inc.